- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BBT-877, Single dose, Placebo group, BBT-877, Multiple doses
- Drug
- Lead sponsor
- Bridge Biotherapeutics, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1033–1056
of 1,076
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Jonathan B. Zuckerman
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Portland, Maine
- Conditions
- Cystic Fibrosis, Burkholderia Infections
- Interventions
- AZLI, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 34
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- PRM-151 (Zinpentraxin Alfa)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- Not listed
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Sacramento, California • San Diego, California + 37 more
- Conditions
- Exocrine Pancreatic Insufficiency
- Interventions
- ANG003
- Drug
- Lead sponsor
- Anagram Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 16 more
- Conditions
- Lung Disease
- Interventions
- Not listed
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,232 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1978 – 2011
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Scleroderma, Systemic
- Interventions
- Nintedanib, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more
- Conditions
- Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 21 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1999 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- EGCG 300 mg, Placebo for EGCG 300 mg, EGCG 600 mg, Placebo for EGCG 600 mg
- Drug
- Lead sponsor
- Hal Chapman
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Ann Arbor, Michigan • Charlottesville, Virginia
- Conditions
- Cystic Fibrosis
- Interventions
- TEZ/IVA, IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 69
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more
- Conditions
- Cystic Fibrosis (CF), Cystic Fibrosis Gastrointestinal Disease
- Interventions
- Mediterranean diet
- Other
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Manchester, New Hampshire
- Conditions
- Idiopathic Pulmonary Fibrosis, Depression, Anxiety, Depressive Disorder, Anxiety Disorders, Anxiety Depression
- Interventions
- Palliative Care, Standard of Care
- Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cystic Fibrosis
- Interventions
- Nitric Oxide for Inhalation, Nitrogen
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis, Lung Transplant; Complications
- Interventions
- Nintedanib, Placebo Oral Tablet
- Drug
- Lead sponsor
- Temple University
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- COVID-19
- Interventions
- APX-115, Placebo
- Drug
- Lead sponsor
- Aptabio Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Annapolis, Maryland • Wyoming, Michigan + 3 more
- Conditions
- Cystic Fibrosis
- Interventions
- LUM/IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 17
- States / cities
- Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
- Conditions
- Healthy Subjects, Cystic Fibrosis
- Interventions
- Tham, Saline
- Drug
- Lead sponsor
- Lakshmi Durairaj
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Chronic Radiation Dermatitis
- Interventions
- Fractional CO2 laser treatment, No treatment
- Device · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cystic Fibrosis, Quality of Life
- Interventions
- Implementation of Primary Palliative Care Intervention in CF Centers
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • New York, New York
- Conditions
- Lung Infection
- Interventions
- Group 1 will receive 15 Hz, Group 2 will receive 30 Hz, Group 3 will receive 60 Hz, Group 4 will receive 100 Hz, Phase II Optimal Frequency
- Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Cystic Fibrosis
- Interventions
- Home lung function and symptom monitoring
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 14 Years and older
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Seattle, Washington
- Conditions
- Pulmonary Fibrosis
- Interventions
- Not listed
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cystic Fibrosis
- Interventions
- Essential amino acid intake + Leucine vs total AA supplement
- Dietary Supplement
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Milene Saavedra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Denver, Colorado